Iradimed (IRMD) EPS (Weighted Average and Diluted) (2013 - 2026)

Iradimed (IRMD) has 14 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.45 in Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.45, up 21.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.83 (up 18.06% YoY), and the FY2025 annual result was $1.75, up 16.67% from the prior year.
• EPS (Weighted Average and Diluted) slipped to $0.45 in Q1 2026 per IRMD's latest filing, from $0.5 in the prior quarter.
• Over five years, EPS (Weighted Average and Diluted) peaked at $0.5 in Q4 2025 and troughed at $0.2 in Q1 2022.
• A 5-year average of $0.36 and a median of $0.37 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
• On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 116.67% in 2022 and fell as far as 3.23% in 2022.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.3 in 2022, then increased by 20.0% to $0.36 in 2023, then advanced by 11.11% to $0.4 in 2024, then grew by 25.0% to $0.5 in 2025, then fell by 10.0% to $0.45 in 2026.
• Business Quant data shows IRMD's EPS (Weighted Average and Diluted) at $0.45 in Q1 2026, $0.5 in Q4 2025, and $0.43 in Q3 2025.